Barclays
ACHV icon

Barclays’s Achieve Life Sciences ACHV Stock Holding History

Barclays’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Sell
19,994
-28,073
-58% -$134K ﹤0.01% 3929
2026
Q1 		$141K Sell
48,067
-61,965
-56% -$275K ﹤0.01% 3881
2025
Q4 		$547K Buy
110,032
+110,031
+11,003,100% +$480K ﹤0.01% 3792
2025
Q3 		$3 Sell
1
-1,715
-100% -$4.71K ﹤0.01% 5422
2025
Q2 		$3.88K Sell
1,716
-34,585
-95% -$98.5K ﹤0.01% 4994
2025
Q1 		$96.9K Sell
36,301
-17,172
-32% -$53.4K ﹤0.01% 4425
2024
Q4 		$188K Buy
53,473
+5,818
+12% +$26.4K ﹤0.01% 4343
2024
Q3 		$226K Buy
47,655
+35,832
+303% +$164K ﹤0.01% 4230
2024
Q2 		$55.6K Buy
+11,823
New +$57K ﹤0.01% 4167
2020
Q2 		– Sell
-5,671
Closed -$37K – 5489
2020
Q1 		$37K Buy
5,671
+5,670
+567,000% +$54.8K ﹤0.01% 5385
2019
Q4 		$0 Buy
+1
New +$21 ﹤0.01% 6301
2014
Q4 		– Hold
0
– – – 7221
2014
Q3 		– Sell
-19
Closed -$132K – 7631
2014
Q2 		$125K Buy
+19
New +$233K ﹤0.01% 5245
2014
Q1 		– Sell
-4
Closed -$98.3K – 7062
2013
Q4 		$74K Buy
+4
New +$70.2K ﹤0.01% 5896
2013
Q3 		– Sell
-2
Closed -$41.4K – 6817
2013
Q2 		$51K Buy
+2
New +$44.7K ﹤0.01% 6290

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Barclays's ACHV Position: Q2 2026 in Review

Barclays reduced its Achieve Life Sciences (ACHV) stake by 58% in Q2 2026, selling an estimated $134K and leaving 19,994 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #3929.

Barclays first reported a position in ACHV in Q2 2013 and has held it in 14 quarters since. The position peaked at $547K in Q4 2025. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Barclays held 19,994 shares of Achieve Life Sciences worth $131K as of Q2 2026.
  • Barclays sold 28,073 Achieve Life Sciences shares in Q2 2026, an estimated $134K.
  • Achieve Life Sciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3929 holding.
  • Barclays first reported a position in Achieve Life Sciences in Q2 2013 and has held it in 14 quarters since.
  • Barclays's Achieve Life Sciences position peaked at $547K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.